伊马替尼是胃肠间质瘤复发和转移病人目前的标准治疗，对于一些病人行手术切除可改善预后。伊马替尼类药物作为新辅助治疗和辅助治疗手段很有可能有助于预后的进一步改善，但仍需更多临床研究的支持，而且药物治疗的时间等诸多因素有待进一步优化。

Management of recurrent and metastatic gastrointestinal stromal tumors        QIAN Hong-gang, HAO Chun-yi. Department of Hepatopancreatobiliary Surgery, Peking University School of Oncology, Beijing 100142, China
Corresponding author: HAO Chun-yi, E-mail: doctorhao@gmail.com
Abstract    For recurrent and metastatic gastrointestinal stromal tumor（GIST）patients, the standard of care is imatinib and surgical removal of the residual lesions is an option in highly selected patients. The use of imatinib as a neoadjuvant and adjuvant protocol is an emerging treatment choice, but further clinical investments are strongly warranted.